Faron advances bexmarilimab program and shores up finances despite deeper losses in 2025

Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an announcement.

Faron reported audited 2025 results showing continued clinical momentum for lead drug candidate bexmarilimab, with Phase I/II BEXMAB trial data in high-risk myelodysplastic syndromes presented at major oncology meetings and described as among the strongest efficacy outcomes seen in prospective HR-MDS studies. The company secured orphan drug designations for bexmarilimab in MDS from the EMA and FDA and received positive End-of-Phase 2 feedback from the FDA, underpinning its ambition to solidify a leading position in macrophage-based immunotherapy.

Financially, Faron strengthened liquidity through an oversubscribed EUR 12 million share placement and a EUR 35 million unsecured convertible bond facility, enabling repayment of a secured loan and lifting year-end cash to EUR 12.3 million despite a EUR 19.0 million operating loss and negative net assets of EUR 18.5 million. After the reporting period, additional bond-related share exercises and board approval to issue up to 80 million new shares ahead of a planned EUR 40 million rights issue highlight ongoing reliance on equity-linked financing, while board and CFO changes signal further corporate maturation as the company advances toward late-stage development.

More about Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy is a Finnish clinical-stage biopharmaceutical company focused on macrophage-based immunotherapies for cancer. Its lead asset is bexmarilimab, an investigational immunotherapy targeting high-risk myelodysplastic syndromes and other hematological malignancies, with a growing presence at major oncology congresses and support from both European and U.S. regulators.

See more data about FARN stock on TipRanks’ Stock Analysis page.